Skip to main content
Top
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Methodology

Rapid Detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors

Authors: Long N Truong, Shashikant Patil, Sherry S Martin, Jay F LeBlanc, Anil Nanda, Mary L Nordberg, Marie E Beckner

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

Genomic tumor information, such as identification of amplified oncogenes, can be used to plan treatment. The two sources of a brain tumor that are commonly available include formalin-fixed, paraffin-embedded (FFPE) sections from the small diagnostic biopsy and the ultrasonic surgical aspiration that contains the bulk of the tumor. In research centers, frozen tissue of a brain tumor may also be available. This study compared ultrasonic surgical aspiration and FFPE specimens from the same brain tumors for retrieval of DNA and molecular assessment of amplified oncogenes.

Methods

Surgical aspirations were centrifuged to separate erythrocytes from the tumor cells that predominantly formed large, overlying buffy coats. These were sampled to harvest nuclear pellets for DNA purification. Four glioblastomas, 2 lung carcinoma metastases, and an ependymoma were tested. An inexpensive PCR technique, multiplex ligation-dependent probe amplification (MLPA), quantified 79 oncogenes using 3 kits. Copy number (CN) results were normalized to DNA from non-neoplastic brain (NB) in calculated ratios, [tumor DNA]/[NB DNA]. Bland-Altman and Spearman rank correlative comparisons were determined. Regression analysis identified outliers.

Results

Purification of DNA from ultrasonic surgical aspirations was rapid (<3 days) versus FFPE (weeks) and yielded greater amounts in 6 of 7 tumors. Gene amplifications up to 15-fold corresponded closely between ultrasonic aspiration and FFPE assays in Bland-Altman analysis. Correlation coefficients ranged from 0.71 to 0.99 using 3 kit assays per tumor. Although normalized CN ratios greater than 2.0 were more numerous in FFPE specimens, some were found only in the ultrasonic surgical aspirations, consistent with tumor heterogeneity. Additionally, CN ratios revealed 9 high-level (≥ 6.0) gene amplifications in FFPE of which 8 were also detected in the ultrasonic aspirations at increased levels. The ultrasonic aspiration levels of these amplified genes were also greater than 6.0 CN ratio, except in one case (3.53 CN ratio). Ten of 17 mid-level (≥3.0 & <6.0 CN ratio) amplifications detected in FFPE were also detected as being increased (≥ 2.0 CN ratio) in the aspirations.

Conclusions

Buffy coats of centrifuged ultrasonic aspirations contained abundant tumor cells whose DNA permitted rapid, multiplex detection of high-level oncogene amplifications that were confirmed in FFPE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Flamm ES, Ransohoff J, Wuchinich D, Broadwin B: Preliminary experience with ultrasonic aspiration in neurosurgery. Neurosurgery. 1978, 2: 240-45. 10.1227/00006123-197805000-00010.CrossRefPubMed Flamm ES, Ransohoff J, Wuchinich D, Broadwin B: Preliminary experience with ultrasonic aspiration in neurosurgery. Neurosurgery. 1978, 2: 240-45. 10.1227/00006123-197805000-00010.CrossRefPubMed
2.
go back to reference Beckner ME, Jane EP, Jankowitz B, Agostino NR, Walter KA, Hamilton RL, Pollack IF, Hamilton RL: Tumor cells from ultrasonic aspirations of glioblastomas migrate and form spheres with radial outgrowth. Cancer Lett. 2007, 255: 135-44. 10.1016/j.canlet.2007.04.005.PubMedCentralCrossRefPubMed Beckner ME, Jane EP, Jankowitz B, Agostino NR, Walter KA, Hamilton RL, Pollack IF, Hamilton RL: Tumor cells from ultrasonic aspirations of glioblastomas migrate and form spheres with radial outgrowth. Cancer Lett. 2007, 255: 135-44. 10.1016/j.canlet.2007.04.005.PubMedCentralCrossRefPubMed
3.
go back to reference Finley JL, Silverman JF, Dickens MA: Immunocytochemical evaluation of central nervous system tumors obtained by the Cavitron ultrasonic surgical aspirator. Diagn Cytopathol. 1990, 6: 308-12. 10.1002/dc.2840060504.CrossRefPubMed Finley JL, Silverman JF, Dickens MA: Immunocytochemical evaluation of central nervous system tumors obtained by the Cavitron ultrasonic surgical aspirator. Diagn Cytopathol. 1990, 6: 308-12. 10.1002/dc.2840060504.CrossRefPubMed
4.
go back to reference Oakes WJ, Friedman HS, Bigner SH, Bullock NH, Bigner DD: Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples, Technical note. J Neurosurg. 1990, 72: 821-23. 10.3171/jns.1990.72.5.0821.CrossRefPubMed Oakes WJ, Friedman HS, Bigner SH, Bullock NH, Bigner DD: Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples, Technical note. J Neurosurg. 1990, 72: 821-23. 10.3171/jns.1990.72.5.0821.CrossRefPubMed
5.
go back to reference Beckner ME, Sampath R, Flowers AB, Katira K, D’Souza D, Patil S, Patel RB, Nordberg ML, Nanda A: Low level amplification of oncogenes correlates inversely with age for patients with non-typical meningiomas. World Neurosurgery. 2011, Available online Nov 7. Beckner ME, Sampath R, Flowers AB, Katira K, D’Souza D, Patil S, Patel RB, Nordberg ML, Nanda A: Low level amplification of oncogenes correlates inversely with age for patients with non-typical meningiomas. World Neurosurgery. 2011, Available online Nov 7.
6.
go back to reference Parsons DW, Jones S, Zhang X, Lin C-HJ, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al.: An integrated genomic analysis of human glioblastoma multiforme. Science. 2008, 321: 1807-12. 10.1126/science.1164382.PubMedCentralCrossRefPubMed Parsons DW, Jones S, Zhang X, Lin C-HJ, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al.: An integrated genomic analysis of human glioblastoma multiforme. Science. 2008, 321: 1807-12. 10.1126/science.1164382.PubMedCentralCrossRefPubMed
7.
go back to reference Albertson DG: Gene amplification in cancer. Trends Genet. 2006, 2006 (22): 447-55.CrossRef Albertson DG: Gene amplification in cancer. Trends Genet. 2006, 2006 (22): 447-55.CrossRef
8.
go back to reference Hastings PJ: Adaptive amplification. Crit Rev Biochem Mol Biol. 2007, 42: 271-83. 10.1080/10409230701507757.CrossRefPubMed Hastings PJ: Adaptive amplification. Crit Rev Biochem Mol Biol. 2007, 42: 271-83. 10.1080/10409230701507757.CrossRefPubMed
9.
go back to reference Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH: Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diag Pathol. 2010, 5: 18-10.1186/1746-1596-5-18.CrossRef Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH: Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diag Pathol. 2010, 5: 18-10.1186/1746-1596-5-18.CrossRef
10.
go back to reference Lopez-Gines C, Gil-Benso R, Ferrer-Luna R, Benito R, Serna E, Gonzalez-Darder J, Quilis V, Monleon D, Celda B, Cerdá-Nicolas M: New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Mod Pathol. 2010, 23: 856-65. 10.1038/modpathol.2010.62.CrossRefPubMed Lopez-Gines C, Gil-Benso R, Ferrer-Luna R, Benito R, Serna E, Gonzalez-Darder J, Quilis V, Monleon D, Celda B, Cerdá-Nicolas M: New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Mod Pathol. 2010, 23: 856-65. 10.1038/modpathol.2010.62.CrossRefPubMed
11.
go back to reference Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S, McLendon R, Wesseling P: Robust detection of EGFR copy number changes and EGFR variant III: Technical aspects and relevance for glioma diagnostics. Brain Pathol. 2009, 19: 661-71. 10.1111/j.1750-3639.2009.00320.x.PubMedCentralCrossRefPubMed Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S, McLendon R, Wesseling P: Robust detection of EGFR copy number changes and EGFR variant III: Technical aspects and relevance for glioma diagnostics. Brain Pathol. 2009, 19: 661-71. 10.1111/j.1750-3639.2009.00320.x.PubMedCentralCrossRefPubMed
12.
go back to reference Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Eng J Med. 2005, 353: 2012-24. 10.1056/NEJMoa051918.CrossRefPubMed Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Eng J Med. 2005, 353: 2012-24. 10.1056/NEJMoa051918.CrossRefPubMed
13.
go back to reference Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, et al.: Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncol. 2006, 8: 67-78. 10.1215/S1522851705000451.PubMedCentralCrossRefPubMed Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, et al.: Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncol. 2006, 8: 67-78. 10.1215/S1522851705000451.PubMedCentralCrossRefPubMed
14.
go back to reference Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, et al.: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009, 27: 579-84.PubMedCentralCrossRefPubMed Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, et al.: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009, 27: 579-84.PubMedCentralCrossRefPubMed
15.
go back to reference Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, et al.: North American Brain Tumor Consortium: A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncol. 2010, 12: 95-103. 10.1093/neuonc/nop015.PubMedCentralCrossRefPubMed Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, et al.: North American Brain Tumor Consortium: A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncol. 2010, 12: 95-103. 10.1093/neuonc/nop015.PubMedCentralCrossRefPubMed
16.
go back to reference Rao SK, Edwards J, Joshi AD, Siu I-M, Riggins GJ: A survey of glioblastoma genomic amplifications and deletions. J Neurooncol. 2010, 96: 169-79. 10.1007/s11060-009-9959-4.CrossRefPubMed Rao SK, Edwards J, Joshi AD, Siu I-M, Riggins GJ: A survey of glioblastoma genomic amplifications and deletions. J Neurooncol. 2010, 96: 169-79. 10.1007/s11060-009-9959-4.CrossRefPubMed
17.
go back to reference Ruano Y, Mollejo M, Ribalta T, Fiano C, Camacho FI, Gomez E, de Lope AR, Hernández-Moneo JL, Martínez P, Meléndez B: Identification of novel candidate target genes in amplicons of glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol Cancer. 2006, 5: 39-PubMedCentralCrossRefPubMed Ruano Y, Mollejo M, Ribalta T, Fiano C, Camacho FI, Gomez E, de Lope AR, Hernández-Moneo JL, Martínez P, Meléndez B: Identification of novel candidate target genes in amplicons of glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol Cancer. 2006, 5: 39-PubMedCentralCrossRefPubMed
18.
go back to reference Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P, Gonzalez-Darder J, Cerdá-Nicolas M, Lopez-Gines C: Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features. Neuropathology. 2010, 30: 392-400.CrossRefPubMed Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P, Gonzalez-Darder J, Cerdá-Nicolas M, Lopez-Gines C: Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features. Neuropathology. 2010, 30: 392-400.CrossRefPubMed
19.
go back to reference Fischer U, Leidinger P, Keller A, Folarin A, Ketter R, Graf N, Lenhof HP, Meese E: Amplicons on chromosome 12q13-21 in glioblastoma recurrences. Int J Cancer. 2010, 126: 2594-602.PubMed Fischer U, Leidinger P, Keller A, Folarin A, Ketter R, Graf N, Lenhof HP, Meese E: Amplicons on chromosome 12q13-21 in glioblastoma recurrences. Int J Cancer. 2010, 126: 2594-602.PubMed
20.
go back to reference Maas RM, Reus K, Diesel B, Steudel WI, Feiden W, Fischer U, Meese E: Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1, alpha-hydroxylase (CYP27B1) in human malignant glioma. Clin Cancer Res. 2001, 7: 868-75.PubMed Maas RM, Reus K, Diesel B, Steudel WI, Feiden W, Fischer U, Meese E: Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1, alpha-hydroxylase (CYP27B1) in human malignant glioma. Clin Cancer Res. 2001, 7: 868-75.PubMed
21.
go back to reference Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Lenhof HP, Meese E, Alsner J, Stemke-Hale K, et al.: Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009, 15: 3654-62. 10.1158/1078-0432.CCR-08-3293.PubMedCentralCrossRefPubMed Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Lenhof HP, Meese E, Alsner J, Stemke-Hale K, et al.: Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009, 15: 3654-62. 10.1158/1078-0432.CCR-08-3293.PubMedCentralCrossRefPubMed
22.
go back to reference Etemadmoghadam D: deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, et al: AOCS Study Group: Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009, 15: 1417-27. 10.1158/1078-0432.CCR-08-1564.PubMedCentralCrossRefPubMed Etemadmoghadam D: deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, et al: AOCS Study Group: Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009, 15: 1417-27. 10.1158/1078-0432.CCR-08-1564.PubMedCentralCrossRefPubMed
23.
go back to reference Moelans CB, de Weger RA, van Blokland MTM, Ezendam C, Elshof S, Tilanus MG, van Diest PJ: Her- 2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cellular Oncol. 2009, 31: 1-10. Moelans CB, de Weger RA, van Blokland MTM, Ezendam C, Elshof S, Tilanus MG, van Diest PJ: Her- 2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cellular Oncol. 2009, 31: 1-10.
24.
go back to reference Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ: Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol. 2010, 23: 62-70. 10.1038/modpathol.2009.136.CrossRefPubMed Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ: Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol. 2010, 23: 62-70. 10.1038/modpathol.2009.136.CrossRefPubMed
Metadata
Title
Rapid Detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors
Authors
Long N Truong
Shashikant Patil
Sherry S Martin
Jay F LeBlanc
Anil Nanda
Mary L Nordberg
Marie E Beckner
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-66

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue